CEMEX, S.A.B. de C.V. (NYSE:CX) caters to the Industrial Goods space. It has a net profit margin of -3.20% and weekly performance is -1.38%. On the last day of trading company shares ended up at $6.43. CEMEX, S.A.B. de C.V. (NYSE:CX) distance from 50-day simple moving average (SMA50) is -12.65%.
Cemex SAB de CV (NYSE:CX) was downgraded by investment analysts at Santander from a “buy” rating to a “hold” rating in a research note issued to investors on Tuesday.
Netlist Inc. (NASDAQ:NLST) ended the last trading day at $0.59. Company weekly volatility is calculated as 12.93% and price to cash ratio as 1.80. Netlist Inc. (NASDAQ:NLST) showed a weekly performance of 1.72%.
Netlist, Inc. (NASDAQ: NLST), announced that it will report its financial results for the third quarter endedSeptember 26, 2015, after 4:00 p.m. Eastern Timeon Tuesday, November 10, 2015, and will host a conference call at 5:00 p.m. Eastern Timethat same day.
On 03 November, Energy XXI Ltd (NASDAQ:EXXI) shares advanced 9.60% and was closed at $1.94. EXXI EPS growth in last 5 year was 5.16%. Energy XXI Ltd (NASDAQ:EXXI) year to date (YTD) performance is -40.49%.
Energy XXI (NASDAQ:EXXI) announced it will host a conference call on Monday, November 9, 2015 at 9 a.m. CT to discuss fiscal 2016 first-quarter results for the period ended September 30, 2015
AbbVie Inc. (NYSE:ABBV) shares decreased -1.50% in last trading session and ended the day at $62.43. ABBV Gross Margin is 80.70% and its has a return on assets of 6.10%. AbbVie Inc. (NYSE:ABBV) quarterly performance is -10.38%.
AbbVie (NASDAQ:ABBV) declared a quarterly dividend on Monday, November 2nd. Investors of record on Friday, January 15th will be paid a dividend of 0.57 per share on Tuesday, February 16th. This represents a $2.28 dividend on an annualized basis and a yield of 3.60%. The ex-dividend date is Wednesday, January 13th. This is an increase from AbbVie’s previous quarterly dividend of $0.51.
Amicus Therapeutics, Inc. (NASDAQ:FOLD) caters to the Healthcare space. Its weekly performance is 28.53%. On the last day of trading company shares ended up at $8.83. Amicus Therapeutics, Inc. (NASDAQ:FOLD) distance from 50-day simple moving average (SMA50) is 6.82%.
Amicus Therapeutics, Inc. (NASDAQ:FOLD), announced financial results for the third quarter ended September 30, 2015. The Company also provided program updates and reiterated financial guidance for 2015 year ending cash balance of $200-$225 million. John F. Crowley, Chairman and Chief Executive Officer of Amicus Therapeutics, Inc., stated, “During the third quarter we made significant progress in executing our patient-centric vision to build one of the world’s leading biotechnology companies focused on devastating rare and orphan diseases.
Leave a Reply